A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment
Public ClinicalTrials.gov record NCT06147830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multinational Observational Longitudinal Study to Describe the Patient Characteristics, Health Care Interventions, and Health Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of insight on treatment approaches and associated outcomes in hospitalized patients with Factor Xa inhibitor-related major bleeds may inform clinical guidelines, health system decision making and streamline treatment pathways in this population.
Study identification
- NCT ID
- NCT06147830
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 2,202 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2023 (Actual)
- Primary completion
- Nov 30, 2024 (Actual)
- Completion
- Nov 30, 2024 (Actual)
- Last update posted
- Nov 3, 2025
2023 – 2024
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Chandler | Arizona | 85224 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | Torrance | California | 90509 | — |
| Research Site | Lakewood | Colorado | 80228-1527 | — |
| Research Site | Hartford | Connecticut | 06102 | — |
| Research Site | Orlando | Florida | 32803 | — |
| Research Site | Tampa | Florida | 33606 | — |
| Research Site | Glenview | Illinois | 60026 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Lexington | Kentucky | 40536 | — |
| Research Site | Royal Oak | Michigan | 48073 | — |
| Research Site | Kansas City | Missouri | 64111 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | New Hyde Park | New York | 11040 | — |
| Research Site | Staten Island | New York | 10305 | — |
| Research Site | Stony Brook | New York | 11794 | — |
| Research Site | Valhalla | New York | 10595 | — |
| Research Site | Chapel Hill | North Carolina | 27514 | — |
| Research Site | Columbus | Ohio | 43210 | — |
| Research Site | Toledo | Ohio | 43614 | — |
| Research Site | Portland | Oregon | 97201-3098 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06147830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 3, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06147830 live on ClinicalTrials.gov.